ZURICH (Reuters) - Swiss pharma group Novartis AG said on Monday it had entered into a clinical collaboration with Bristol-Myers Squibb Co to evaluate the safety and efficacy of combination treatments for patients with non-small cell lung cancer. The collaboration will help Novartis further advance its efforts in the field of immunotherapy, following the acquisition of CoStim Pharmaceuticals Inc this year, Novartis said in a statement. ...
via Health News Headlines - Yahoo News Read More Here..
No comments:
Post a Comment